Immix Biopharma, Inc.

Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.

IMMX | NDAQ

Overview

Corporate Details

ISIN(s):: US45258H1068
LEI:
Country:: United States of America
Address:: 11400 WEST OLYMPIC BLVD., 90064 LOS ANGELES
Website:: https://immixbio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing advanced cell therapies. The company's primary focus is on pioneering treatments for AL Amyloidosis, hematologic malignancies, and other serious diseases with unmet medical needs. A core part of its strategy is to overcome the challenge of neurotoxicity, a significant side effect that currently limits the widespread adoption of Chimeric Antigen Receptor T-cell (CAR-T) therapies. By developing safer cell therapies, ImmixBio aims to expand treatment accessibility to a broader patient population and enable administration in a greater number of medical centers. The company collaborates with industry leaders to accelerate its research and development efforts.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Immix Biopharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Immix Biopharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Immix Biopharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Calliditas Therapeutics Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.	Sweden	CALTX
CALTH. Inc Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.	South Korea	402420
CAMBRIDGE NUTRITIONAL SCIENCES PLC Develops and manufactures diagnostic tests for food sensitivity and gut health.	United Kingdom	CNSL
Camp4 Therapeutics Corp Developing RNA-based therapies to upregulate genes for rare metabolic and CNS disorders.	United States of America	CAMP
Camurus Develops long-acting medicines for severe chronic diseases using advanced drug delivery.	Sweden	CAMX
CanBas Co.,Ltd. Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.	Japan	4575
Candel Therapeutics, Inc. Developing off-the-shelf viral immunotherapies to help the immune system fight solid tumors.	United States of America	CADL
Can-Fite BioPharma Ltd. Clinical-stage biopharma developing oral drugs for cancer, inflammatory, liver & metabolic diseases.	United States of America	CANF
Can-Fite BioPharma Ltd. Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.	Israel	CANF
Cannovum Cannabis AG Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.	Germany	27N0